|
|
|
| Effect of modified Xijiao Dihuang Decoction on primary immunologic thrombocytopenic purpura and the level of T lymphocyte subsets |
| ZENG Hui ZHAO Xiaoyan YAN Minchao SHEN Mingfang |
| Department of Hematology, the First Hospital of Jiaxing, Zhejiang Province, Jiaxing 314000, China |
|
|
|
Abstract Objective To analyze the effect of modified Xijiao Dihuang Decoction on primary immunologic thrombocytopenic purpura and the level of T lymphocyte subsets. Methods A total of 76 patients with primary immunologic thrombocytopenic purpura admitted to the First Hospital Jiaxing from January 2016 to February 2018 were selected for this study. According to the random number table method, they were randomly divided into conventional group and traditional Chinese medicine group, 38 cases in each group. The conventional group was treated with Prednisone Acetate Tablets, while the traditional Chinese medicine group was treated with modified Xijiao Dihuang Decoction (buffalo horn instead of rhino horn). After treatment, the effects total effective rate and relapse rate, traditional Chinese medicine symptom score, platelet count and T lymphocyte subsets CD3+, CD4+ and CD8+ of the two groups were compared. Results After treatment, there was no significant difference in the total effective rate and relapse rate between the two groups (P ＞ 0.05). After treatment, the total effective rate of traditional Chinese medicine symptom improvement in traditional Chinese medicine group was higher than that in the conventional group (P ＜ 0.05). After treatment, the platelet count of the two groups increased (P ＜ 0.05), but there was no significant difference between the two groups (P ＞ 0.05). After treatment, the levels of CD3+ and CD4+ in the two groups were higher, and the traditional Chinese medicine group were higher than those in the conventional group (P ＜ 0.05); the levels of CD8+ in the two groups were lower, and the traditional Chinese medicine group was lower than that in the conventional group (P ＜ 0.05). There were no adverse reactions in the two groups during the study. Conclusion Modified Xijiao Dihuang Decoction has a significant effect in the treatment of primary immunologic thrombocytopenic purpura, it can obviously improve the clinical symptoms of patients and the level of T lymphocyte subsets.
|
|
|
|
|
|
[1] 侯文沛，胡琦.原发免疫性血小板减少症发病机制的研究进展[J].山东医药，2016，56（2）：104-106.
[2] Samson M，Fraser W，Lebowitz D. Treatments for Primary Immune Thrombocytopenia：A Review [J]. Cureus，2019， 11（10）：e5849.
[3] Care A，Pavord S，Knight M，et al. Severe primary autoimmune thrombocytopenia in pregnancy：a national cohort study [J].BJOG，2018，125（5）：604-612.
[4] 陈玙，王梅芳，陈剑芳，等.成人原发免疫性血小板减少症161例疗效及预后的影响因素分析[J].中华全科医师杂志，2018，17（10）：794.
[5] 唐世锋，杜忠海.中医药治疗原发性血小板减少性紫癜的临床研究进展[J].河北中医，2013，35（3）：467-470.
[6] 吴玉霞，袁忠，马西虎，等.从脾论治慢性原发性免疫性血小板减少性症临床疗效观察[J].世界中医药，2016，11（9）：1782-1785.
[7] Sest?覬l HG，Trangb?覸k SM，Bussel JB，et al. Health-related quality of life in adult primary immune thrombocytopenia [J]. Expert Rev Hematol，2018，11（12）：975-985.
[8] Monteagudo E，Astigarraga I，Cervera ?譧，et al. Protocol for the study and treatment of primary immune thrombocytopenia： PTI-2018 [J]. An Pediatr：Barc，2019，91（2）：127.e1-127.e10.
[9] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识（2016年版）[J].中华血液学杂志，2016，37（2）：89-93.
[10] 侯明，秦平.成人原发免疫性血小板减少症诊治的中国专家共识（2016版）解读[J].临床血液学杂志，2016，30（4）：523-527.
[11] Provan D，Arnold DM，Bussel JB，et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia [J]. Blood Adv，2019，3（22）：3780-3817.
[12] 张之南，沈悌.血液病诊断及疗效标准[M].3版.北京：科学出版社，2007：172-176.
[13] 郑筱萸.中药新药临床研究指导原则[M].北京：中国中医药科技出版社，2002：181-182.
[14] 卢雨萌，程韵枫.原发免疫性血小板减少症中调节性T淋巴细胞的异常[J].中国临床医学，2016，23（5）：672-676.
[15] 熊婷婷，谢晓恬.免疫性血小板减少症的细胞免疫致病机制研究最新进展[J].中国小儿血液与肿瘤杂志，2019， 24（6）：321-327.
[16] 曹红刚，吴涛，薛锋，等.原发免疫性血小板减少症脾切除术后继发非特指型外周T细胞淋巴瘤一例并文献复习[J].中国医师杂志，2019，21（4）：621-622.
[17] 张瑞峰，鲍计章，周永明.从脾肾论治原发免疫性血小板减少症研究进展[J].中医学报，2020，35（2）：285-290.
[18] 沈静涵，周韶虹.原发免疫性血小板减少症的中医药治疗进展[J].天津药学，2015，27（6）：68-69，74.
[19] 刘晓翔，侯雅军.柯微君治疗特发性血小板减少性紫癜经验介绍[J].新中医，2019，51（4）：315-317.
[20] 杨冉，林琳，姚浩，等.基于数据挖掘的慢性原发免疫性血小板减少症用药规律分析[J].中国中医基础医学杂志，2020，26（3）：350-353.
[21] 袁永平，杨翔，陈懿建.原发性免疫性血小板减少症的发病机制研究进展[J].中国实验血液学杂志，2019，27（5）：1706-1710.
[22] 王跃，江劲波，聂甜，等.犀角地黄汤对免疫性血小板减少症模型大鼠外周血CD4~+CD25~+调节性T细胞及Th17细胞的影响[J].现代中西医结合杂志，2018，27（6）：571-575.
[23] 徐皓，鲍计章，周永明.原发免疫性血小板减少症的发病机制的研究进展[J].医学研究杂志，2019，48（11）：184-187，176.
[24] 王佳，高峰，杨学文.加味犀角地黄汤含药血清对人微血管内皮细胞增殖的影响[J].中医药导报，2016，23（16）：18-21.
[25] 杨润田.犀角地黄汤加减治疗免疫性血小板减少症临床研究[J].临床医药文献电子杂志，2018，5（96）：148. |
|
|
|
